

Reference:	FOI.19069.25
Subject:	HIV and for Pre-exposure Prophylaxis (PrEP) treatment
Date of Request:	9 December 2025

Requested:

1. How many patients were treated in the last 6-month period with branded or generic emtricitabine / tenofovir disoproxil fumarate (Truvada) for HIV treatment?
2. How many patients were treated in the last 6-month period with branded or generic emtricitabine / tenofovir disoproxil fumarate for Pre-exposure prophylaxis (PrEP)?
3. How many packs of branded or generic emtricitabine / tenofovir disoproxil fumarate were dispensed in latest 6-month period for HIV treatment?
4. How many packs of branded or generic emtricitabine / tenofovir disoproxil fumarate were dispensed in latest 6-month period for Pre-exposure prophylaxis (PrEP)?
5. How many patients were treated in the last 6-month period with tenofovir alafenamide / emtricitabine (Descovy) for HIV treatment?
6. How many patients were treated in the last 6-month period with tenofovir alafenamide / emtricitabine for Pre-exposure prophylaxis (PrEP)?
7. How many packs of tenofovir alafenamide / emtricitabine were dispensed in latest 6-month period for HIV treatment?
8. How many packs of tenofovir alafenamide / emtricitabine were dispensed in latest 6-month period for Pre-exposure prophylaxis (PrEP)?

Response:

Hywel Dda University Health Board (UHB) does not hold the information requested for HIV treatment as it does not provide treatment for HIV patients. The treatment of HIV for UHB patients is undertaken via Swansea Bay University Health Board (SBUHB). Therefore, we recommend that you redirect this part of your request to the Freedom of Information Team at SBUHB who may be able to help you further. The contact details are as follows:

FOIA.Requests@wales.nhs.uk or alternatively, you can contact: FOIA Team, Swansea Bay University Health Board, Health Board Headquarters, 1 Talbot Gateway, Port Talbot, SA12 7BR.

Hywel Dda University Health Board (UHB) provides within the table below the medication supplied by the Sexual and Reproductive Health service as recorded on the UHB's Sexual Health Management IT system (Lillie) between 1 June and 31 December 2025 for pre-exposure prophylaxis only.

It should be noted that the numbers reflect individual patient contacts accessing this service during this time period, some patients may have had more than one consultation and will be counted multiple times.

Number	Question	Response
1	How many patients were treated in the last 6-month period with branded or generic emtricitabine / tenofovir disoproxil fumarate (Truvada) for HIV treatment?	0
2	How many patients were treated in the last 6-month period with branded or generic emtricitabine / tenofovir disoproxil fumarate for Pre-exposure prophylaxis (PrEP)?	274
3	How many packs of branded or generic emtricitabine / tenofovir disoproxil fumarate were dispensed in latest 6-month period for HIV treatment?	0
4	How many packs of branded or generic emtricitabine / tenofovir disoproxil fumarate were dispensed in latest 6-month period for Pre-exposure prophylaxis (PrEP)?	854
5	How many patients were treated in the last 6-month period with tenofovir alafenamide / emtricitabine (Descovy) for HIV treatment?	0
6	How many patients were treated in the last 6-month period with tenofovir alafenamide / emtricitabine for Pre-exposure prophylaxis (PrEP)?	0
7	How many packs of tenofovir alafenamide / emtricitabine were dispensed in latest 6-month period for HIV treatment?	0
8	How many packs of tenofovir alafenamide / emtricitabine were dispensed in latest 6-month period for Pre-exposure prophylaxis (PrEP)?	0